Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NY-ESO-1 OLP4 + Montanide
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Peptides, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
NY-ESO-1 OLP4 + Montanide is a therapeutic cancer vaccine composed of four long overlapping synthetic peptides (OLP4) derived from the immunogenic cancer-testis antigen NY‑ESO‑1, combined with the adjuvant Montanide ISA 51. The vaccine is designed to stimulate both humoral and cellular immune responses against tumors expressing NY‑ESO‑1. The overlapping peptide approach covers most T cell epitopes within residues 79–173 of the protein, maximizing immunogenicity and minimizing HLA restriction[2][3][4]. Montanide acts as an incomplete Freund’s adjuvant to enhance antigen presentation and immune activation. This combination has been studied primarily in ovarian epithelial carcinoma, fallopian tube carcinoma, and primary peritoneal carcinoma[3][5]. Clinical trials have shown that adding Montanide increases CD8+ T-cell cross priming and enhances T-cell avidity for the target antigen[1].
- Other names
- NY-ESO-1 OLP4 + Montanide
02
Targets
MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on NY-ESO-1 OLP4 + Montanide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NY-ESO-1 OLP4 + Montanide.